Letter by Gordon et al regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study"

Circulation

Volumn 125, Issue 8, 2012, Pages

  Gordon, Brian ^a   McDiarmid, Adam ^a   MacGowan, Guy ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; CHLORTALIDONE; DIURETIC AGENT; FUROSEMIDE; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL;

BLOOD PRESSURE; CARDIOPULMONARY HEMODYNAMICS; ENZYME INHIBITION; FLUID BALANCE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART RIGHT ATRIUM PRESSURE; HOSPITALIZATION; HUMAN; LETTER; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; VENOUS PRESSURE;

FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; STROKE VOLUME; SULFONES;

EID: 84857943062     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.056259     Document Type: Letter

References (2)

1. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174.
2. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009;119:1977-2016.